180 Wealth Advisors LLC Sells 538 Shares of Illumina, Inc. (NASDAQ:ILMN)

180 Wealth Advisors LLC decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 2.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,168 shares of the life sciences company’s stock after selling 538 shares during the period. 180 Wealth Advisors LLC’s holdings in Illumina were worth $2,695,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ILMN. Versant Capital Management Inc lifted its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the period. TD Private Client Wealth LLC lifted its position in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the period. Massmutual Trust Co. FSB ADV boosted its stake in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Private Trust Co. NA increased its position in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after buying an additional 212 shares during the period. Finally, Focused Wealth Management Inc bought a new position in Illumina in the third quarter worth about $63,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on ILMN shares. Barclays lifted their price objective on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. UBS Group upped their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Leerink Partners lifted their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $165.63.

Illumina Trading Up 5.5 %

Illumina stock opened at $144.22 on Tuesday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The company has a market cap of $22.87 billion, a P/E ratio of -14.48 and a beta of 1.11. The business has a 50-day simple moving average of $140.92 and a two-hundred day simple moving average of $132.88. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 EPS. Analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.